GLP-1 Side Effects: What to Expect and How to Manage Them

Side effects are the most common reason patients discontinue GLP-1 medications. In the STEP 1 trial, about 7 percent of participants on semaglutide stopped treatment because of adverse events, compared to 3 percent on placebo. For tirzepatide in SURMOUNT-1, the discontinuation rate due to side effects was similar — around 6 percent at the highest dose.

Those numbers mean that the vast majority of patients tolerate these drugs well enough to continue. But the first several weeks can be rough, and knowing what to expect — and what warrants a call to your doctor — makes a real difference in whether someone pushes through or gives up.

The Gastrointestinal Effects: Why They Happen

The dominant side effect category for every GLP-1 agonist is gastrointestinal. Nausea, vomiting, diarrhea, constipation, and abdominal discomfort show up in virtually every trial, and they show up at rates that are hard to dismiss as trivial.

These symptoms are not incidental. They are a direct consequence of the drug's mechanism of action. GLP-1 receptors line the gastrointestinal tract, and activating them slows gastric emptying — food sits in the stomach longer than the body is used to. The brainstem's area postrema, which mediates nausea, is also rich in GLP-1 receptors. When a patient starts a GLP-1 agonist, they are essentially telling their gut to behave very differently than it has been, and the gut protests.

The good news is that for most patients, these effects are transient. They peak during dose escalation (the first 8 to 16 weeks, depending on the drug) and then diminish substantially. The gastrointestinal tract adapts. By the time patients reach their maintenance dose, the majority report that nausea has resolved or become negligible.

Side Effect Rates by Medication

Data from STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) prescribing information. Rates are for the highest approved doses.

A few observations from this data. Semaglutide has higher nausea and vomiting rates than tirzepatide at their respective highest doses. However, direct head-to-head comparisons are limited, and the trial populations differed. Constipation appears more common with semaglutide, while injection site reactions are somewhat more frequent with tirzepatide.

Practical Strategies for Managing GI Side Effects

These recommendations come from prescribing guidelines, clinical experience, and the FDA-approved labels. None of them are complicated, but they make a meaningful difference for patients who are struggling.

For Nausea

• Eat smaller meals. Three large meals a day is a bad fit for a stomach that is emptying slowly. Switch to four or five smaller portions.
• Avoid high-fat and fried foods. Fat slows gastric emptying on its own, and the combination with a GLP-1 agonist can be miserable.
• Do not lie down immediately after eating. Give gravity 30 to 60 minutes to help things move.
• Stay hydrated. Sip water or ginger tea throughout the day. Dehydration worsens nausea and increases the risk of kidney injury.
• Ask about slower titration. If nausea is severe, your doctor can extend the time at each dose level from four weeks to six or eight. There is no requirement to rush to the maintenance dose.

For Constipation

• Increase dietary fiber gradually (25 to 30 grams per day is the target).
• Drink at least 64 ounces of water daily.
• Physical activity — even walking — stimulates gut motility.
• If these measures are insufficient, over-the-counter osmotic laxatives (polyethylene glycol) are generally safe to use with GLP-1 medications.

For Diarrhea

• This usually resolves on its own within the first few weeks.
• Maintain hydration and electrolyte intake.
• Avoid sugar-free candies and drinks containing sorbitol, which can worsen diarrhea.
• If persistent and severe, contact your prescriber — the dose may need adjustment.

Serious Side Effects: What the Evidence Shows

Beyond the GI symptoms, there are several serious adverse events that appear in the prescribing information for GLP-1 medications. Understanding their actual incidence — rather than simply knowing they exist — is important for informed decision-making.

Pancreatitis

Acute pancreatitis has been reported in patients taking GLP-1 agonists. In the STEP and SURMOUNT trials, the incidence was low — less than 0.2 percent in both the drug and placebo groups, with no statistically significant difference between them. A large meta-analysis published in The Lancet Diabetes & Endocrinology in 2023, pooling data from over 60,000 patients across multiple GLP-1 trials, found no increased risk of pancreatitis compared to placebo.

That said, individual cases do occur, and a prior history of pancreatitis is generally considered a relative contraindication. The warning signs are unmistakable: severe, persistent abdominal pain radiating to the back, often with vomiting. If this occurs, stop the medication and seek medical evaluation.

Gallbladder Disease

Gallstones and cholecystitis (gallbladder inflammation) occur at higher rates in patients losing weight rapidly — whether through medication, dieting, or surgery. In the STEP 1 trial, cholelithiasis was reported in 2.6 percent of semaglutide patients versus 1.2 percent on placebo. The mechanism is well understood: rapid weight loss increases cholesterol saturation of bile, promoting stone formation.

This is not unique to GLP-1 medications. Any intervention that produces substantial weight loss carries this risk. Symptoms include right upper quadrant pain (especially after fatty meals), nausea, and sometimes fever. Report these to your doctor promptly.

Kidney Injury

Acute kidney injury has been reported, but in nearly every documented case, the precipitating factor was dehydration — typically from severe and prolonged vomiting or diarrhea. The medication itself does not appear to be directly nephrotoxic. In fact, data from the FLOW trial (published in the NEJM in 2024) showed that semaglutide actually slowed progression of chronic kidney disease in patients with type 2 diabetes and reduced the risk of kidney failure by 24 percent.

The takeaway is straightforward: stay hydrated, and if GI symptoms are severe enough that you cannot keep fluids down, contact your doctor. Patients with pre-existing kidney disease should have their renal function monitored more frequently during dose escalation.

Thyroid Tumors

The boxed warning on every GLP-1 agonist label references thyroid C-cell tumors observed in rodents. This finding led to the contraindication in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2).

However, the relevance to humans is uncertain. Rodents have a much higher density of GLP-1 receptors on thyroid C-cells than humans do. Surveillance data from the FDA Adverse Event Reporting System and large epidemiological studies (including a 2022 analysis in Diabetes Care covering over 300,000 patient-years of GLP-1 exposure) have not identified an increased rate of MTC in humans. The boxed warning remains because the theoretical risk cannot be definitively excluded, but the practical risk appears to be very low.

Diabetic Retinopathy

The SUSTAIN 6 trial with semaglutide found a statistically significant increase in diabetic retinopathy complications (3.0 percent vs. 1.8 percent on placebo). Subsequent analysis suggested this was related to the speed of blood sugar improvement rather than a direct drug effect — rapid glucose normalization can temporarily worsen existing retinopathy, a phenomenon observed with insulin therapy as well. Patients with advanced diabetic eye disease should have their retinopathy monitored when starting a GLP-1 agonist.

Drug Interactions to Be Aware Of

Because GLP-1 agonists slow gastric emptying, they can affect the absorption of oral medications. The clinical significance varies, but a few interactions are worth noting:

• Oral contraceptives: Delayed absorption may reduce peak concentrations. The FDA advises switching to a non-oral contraceptive method or adding a barrier method for 4 weeks after initiating tirzepatide and after each dose increase.
• Levothyroxine: Some patients on thyroid replacement may need TSH monitoring and dose adjustment.
• Warfarin: INR should be monitored more frequently when starting or adjusting a GLP-1 agonist.
• Insulin and sulfonylureas: The risk of hypoglycemia increases significantly. Dose reduction of the insulin or sulfonylurea is often necessary.

When to Call Your Doctor

Most patients taking GLP-1 medications will experience some degree of gastrointestinal discomfort. Most will find it manageable and temporary. Understanding the difference between the common, expected symptoms and the rare but serious ones is the most important thing you can take away from this article.